Biological Activity
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
In Vitro
TSR-011 has antitumour activity in the clinical trials.
In Vivo
TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
